TL;DR
Get workout gear delivered free with Prime
- Fast, free delivery on millions of items
- Prime Video, Amazon Music and more included
- Member-only deals all year
A paper in The Lancet Healthy Longevity argues that sarcopenia should be understood as a condition involving the aging motor system, including the brain, nerves and muscles, rather than muscle loss alone. The authors propose broader clinical measures, but say the new approach has not yet been shown to outperform existing screening or improve outcomes.
A paper published in The Lancet Healthy Longevity argues that age-related weakness and mobility loss should be understood as changes across the motor system—from the brain and spinal cord to nerves and muscle—not simply as muscle wasting. The authors say this reframing could influence how clinicians assess sarcopenia, but they acknowledge that proposed additional measures have not been shown to improve outcomes over current screening.
The authors, led by Lucas B. R. Orssatto, say current definitions of sarcopenia already rely on physical performance measures such as grip strength, walking speed and chair stands, rather than muscle mass alone. Those measures help identify risks including falls and disability. But, they argue, the explanation for declining performance has remained focused too narrowly on muscle.
The paper says muscle loss accounts for only a modest share of strength decline in older adults, and people with similar muscle mass can have very different strength and mobility. The authors point to evidence that exercise can improve strength and movement even when measurable muscle mass does not change. They propose that age-related changes in movement planning, nerve signaling, balance and position sense also shape physical function.
For assessment, the researchers suggest clinicians could look beyond whether someone can stand from a chair to how quickly they rise, and note unsteadiness during sustained effort, hand dexterity and changes in walking while talking. They also recommend closer examination when weakness is asymmetric, rapid or disproportionate to muscle loss. These are proposals for further validation, not a replacement set of established diagnostic criteria.
A Broader View of Mobility Risk
The argument matters because weakness can affect falls, disability and independence, while a muscle-only explanation may not account for why people with similar muscle mass function differently. If the authors’ model is validated, care and research could pay more attention to nerve and motor control alongside muscle strength and size.
The scale of fall injuries gives the issue public-health relevance in Australia. The source report cites 253,800 fall-related hospitalizations in 2024–25 and 6,722 Australians who died following a fall in the preceding year. It also reports an estimated A$5.4 billion in health-system costs from fall injuries. These figures describe the reported Australian burden; they do not establish that the proposed motor-system approach would prevent falls.
The authors argue that the model could guide more targeted assessment and shift research toward interventions that improve everyday function, rather than focusing predominantly on increasing muscle mass. Whether that change would produce better care remains untested.
Products Worth Considering
Bowflex SelectTech 840 Adjustable Kettlebell
BowFlex Results Series SelectTech 552 Adjustable Dumbbell
Bowflex PR1000 Home Gym
As an affiliate, we earn on qualifying purchases.
How Sarcopenia Assessment Has Shifted
Sarcopenia refers to substantial loss of muscle, strength and physical function associated with aging. The Medical Xpress report says it affects up to 29% of community-dwelling older adults, with higher rates among people in hospitals or residential elder care and those with multimorbidity or frailty. The estimate applies to those populations as described; it is not a measure of the proposed motor-system model.
Diagnostic thinking has already moved beyond muscle mass: measures such as grip strength, gait speed and chair stands are used because they can reflect functional consequences. Earlier in 2026, the Australian Journal of General Practice published a proposed primary-care algorithm for screening, assessment and management of poor muscle health, according to the source report. The new paper challenges the assumption that muscle alone explains the decline those tests detect.
The article, Reframing sarcopenia as a disease of the ageing motor system, appeared in The Lancet Healthy Longevity in 2026. It sets out a five-point agenda for international working groups responsible for diagnostic criteria, though the supplied report does not detail each point.
“We think the model is the problem.”
— The authors of the Lancet Healthy Longevity paper
Evidence Needed Before Practice Changes
The paper proposes a broader explanation and assessment agenda; it does not establish that screening for the suggested signs will improve patient outcomes. The authors say there is no evidence yet that the measures outperform existing screens on outcomes or cost. The source report also notes that neuromuscular expertise is not evenly available in primary care.
It remains unclear which practical tests would best distinguish the contributions of muscle, nerves and other parts of the motor system, how reliably primary-care clinicians could use them, and whether acting on the results would reduce falls or preserve independence. The supplied material does not report a clinical trial testing the proposed approach.
Validation and Updated Diagnostic Guidance
The authors call for investment in practical tests that can be validated, guidelines supporting a staged assessment and trials that measure nerve as well as muscle. They have also set out a five-point agenda for international groups that develop sarcopenia diagnostic criteria.
For now, the paper is a proposal rather than a change to established screening guidance. The next significant evidence would be studies testing whether additional motor-system assessments are feasible, whether they add useful information to current measures, and whether interventions guided by them improve strength, mobility or everyday function.
Key Questions
What is sarcopenia?
Sarcopenia is a condition involving substantial loss of muscle, strength and physical function associated with aging. The paper argues that changes outside the muscle may also contribute to weakness and mobility loss.
What does the new paper propose?
The authors propose viewing sarcopenia as a disease of the aging motor system, which includes the brain, spinal cord, nerves and muscles. They suggest that assessment could include movement quality and coordination as well as existing strength and walking measures.
Has the proposed approach been proven to improve outcomes?
No. The authors say the suggested measures have not been shown to outperform existing screens on outcomes or cost. They call for validation studies and trials before the approach can be judged.
What signs do the authors suggest clinicians watch for?
They suggest noting how quickly a person rises from a chair, unsteadiness during sustained effort, hand dexterity and changes in walking while talking. The authors also say rapid or asymmetric weakness, or weakness out of proportion to muscle loss, warrants closer examination.
Source: medicalxpress.com
